Bellerophon Therapeutics, Inc. Form 3 October 23, 2015 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# Washington, D.C. 20549

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB 3235-0104 Number:

Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

f Reporting	<ul><li>2. Date of Event Requiring</li><li>Statement</li><li>(Month/Day/Year)</li></ul>	<ul> <li>3. Issuer Name and Ticker or Trading Symbol</li> <li>Bellerophon Therapeutics, Inc. [BLPH]</li> </ul>				
(Middle)	10/21/2015			5. If Amendment, Date Original Filed(Month/Day/Year)		
		(Check	all applicable)			
)		Director X Officer (give title below	<pre> 10% ( Other y) (specify below)</pre>	Filing(Check Applicable Line)		
WARREN, NJ 07059		VP Clinical Operations & Admin				
(Zip)	Table I - N	Non-Derivati	ive Securiti	es Beneficially Owned		
			3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)		
*	ach class of securities benefic	ially SI	EC 1473 (7-02)	))		
formation conta equired to respo urrently valid Ol	ained in this form are not and unless the form displ MB control number.	ays a	warrants, opt	tions, convertible securities)		
	PRNER (02 (02 (0) (Zip) (Zip) (Zip) (Zip) (czip) (c	Statement (Month/Day/Year) 10/21/2015 (Middle) 10/21/2015 (Middle) 07059 (Zip) Table I - N 2. Amount o Beneficially (Instr. 4) separate line for each class of securities benefic ectly. ersons who respond to the collection of formation contained in this form are not equired to respond unless the form displ urrently valid OMB control number.	Statement (Month/Day/Year)       Bellerophon         (Middle)       10/21/2015       4. Relationship Person(s) to Is         RNER (02       (Check         (0)       (Zip)       Image: Check of the collection o	Statement (Month/Day/Year)       Bellerophon Therapeut         Middle)       10/21/2015       4. Relationship of Reporting Person(s) to Issuer         RNER (02       (Check all applicable)         (0)       (Zip)       — Director (give title below)       10% (specify below)         (Zip)       Table I - Non-Derivative Securitie 2. Amount of Securities Beneficially Owned (Instr. 4)       3. Beneficially Owned (Instr. 4)         (1)       Ownership (Instr. 4)       Form: Direct (D) or Indirect (I) (Instr. 5)         separate line for each class of securities beneficially ectly.       SEC 1473 (7-02         ersons who respond to the collection of formation contained in this form are not equired to respond unless the form displays a       SEC 1473 (7-02		

1. Title of Derivative Security	2. Date Exercisable and		3. Title and Amount of		4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date		Securities Ur	nderlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)		Derivative Security		or Exercise	Form of	(Instr. 5)
			(Instr. 4)		Price of E	Derivative	ivative
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative	Security:	
					Security	Direct (D)	
						or Indirect	
						(I)	

### Edgar Filing: Bellerophon Therapeutics, Inc. - Form 3

						(Instr. 5)	
Stock Option (right to buy)	(1)	06/19/2024	Common Stock	3,991	\$ 13.28	D	Â
Stock Option (right to buy)	(2)	02/12/2025	Common Stock	1,995	\$ 12	D	Â
Stock Option (right to buy)	( <u>3)</u>	03/11/2025	Common Stock	4,400	\$ 10.22	D	Â

## **Reporting Owners**

Reporting Owner Name / Address		Relationships					
		Director	10% Owner	Officer	Other		
Edmonds Amy 184 LIBERTY CORNER R SUITE 302 WARREN, NJ 07059	OAD	Â	Â	VP Clinical Operations & Admin	Â		
Signatures							
/s/ Amy Edmonds	0/23/2	015					
<u>**</u> Signature of	Date						

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This option was granted on June 20, 2014. This option vests as to 25% of the underlying shares on each of the second and third
  (1) anniversaries of February 12, 2014 (the "Vesting Commencement Date") and 50% on the fourth anniversary of the Vesting Commencement Date.
- (2) This option was granted on February 13, 2015. This option vests as to 25% of the underlying shares on each one year anniversary of the date of grant.
- This option vested as to 25% of the underlying shares on March 13, 2015 (the "Vesting Commencement Date") and vests as to an
- (3) This option vested as to 25% of the underlying shares on which is, second and third anniversaries of the Vesting Commencement Date.

### Â

#### **Remarks:**

Reporting Person

#### Exhibit Index: 24.1 Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.